BARD1 and neoplasm: To this end, we implanted PARPi-resistant tumor cells from the Brca1-def and Bard1-def models in the mammary glands of new recipient B6/129F1 mice and treated them with either VEGFR2 antibody (200 μg/mouse three times a week) or isotype control antibody in combination with vehicle or talazoparib (schematic in Fig. 2I).